The current research, development, and regulatory process for drugs and devices is being hampered by inefficiencies that stand in the way of getting safe treatments and cures to patients more quickly and effectively.

That is the conclusion of a report issued Jan. 29 by Senators Lamar Alexander (R-Tenn.) and Richard Burr (R-N.C.) that takes aim at the U.S. Food and Drug Administration and the National Institutes of Health.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access